Extended release formulation of diltiazem hydrochloride

A controlled release pharmaceutical formulation comprising:

• a quantity of at least one pharmaceutically active compound or its salt;
• a first rapid-release component further comprising at least one of said pharmaceutically active compounds or salts, wherein the amount of said at least one active compound or salt further comprises between 1% to 99% of said quantity of said at least one pharmaceutically active compound or salt;
• a second component comprising between 1% to 99% of said quantity of said at least one active compound or salt;
• and
• wherein said second component is characterized by a slower rate of release of said pharmaceutically active compounds or salts, than said first component.

A controlled release pharmaceutical formulation comprising:

• a quantity of a calcium channel blocker derivatives or salts thereof;
• a quick-release component comprising from between 1-99% of said quantity of the calcium channel blocker or derivatives and salts thereof, in said formulation;
• and
• a slower-release component comprising from between 1-99% of the total weight of calcium channel blocker or derivatives and salts thereof.

A method for treating abnormal cardiac activity, said method comprising the steps of:

• obtaining a quantity of a calcium channel blocker or derivatives and salts thereof, comprising both a rapid-release component and a slower-release component, wherein said rapid-release component and said slower-release component are each between 1 to 99% of said quantity of said calcium channel blocker;
• combining said rapid-release and slower-release compositions into a single pharmaceutical formulation suitable to permit simultaneous administering of both of said rapid and slower-release compositions;
• administering said single pharmaceutical formulation to a suitable subject;
• and
• elevating to substantially maximal levels, said subject's blood plasma.level of said calcium channel blocker within 1 to 2 hours, and maintaining substantially the same plasma levels for up to 10-14 hours after administering said pharmaceutical formulation.